Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - mycophenolate mofetil, quantity: 500 mg - tablet, film coated - excipient ingredients: hyprolose; hypromellose; povidone; purified talc; titanium dioxide; croscarmellose sodium; macrogol 400; iron oxide red; iron oxide black; microcrystalline cellulose; magnesium stearate - mycophenolate sandoz is indicated for the prophylaxis of solid organ rejection in adults receiving allogeneic organ transplants. . mycophenolate sandoz is indicated for the prophylaxis of organ rejection in paediatric patients (6 to 18 years) receiving allogeneic renal transplants.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - mycophenolate mofetil, quantity: 500 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; microcrystalline cellulose; pregelatinised maize starch; magnesium stearate; povidone; sodium lauryl sulfate; silicon dioxide; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350 - ceptolate (mycophenolate mofetil) is indicated for the prophylaxis of solid organ rejection in adults receiving allogeneic organ transplants. ceptolate (mycophenolate mofetil) is indicated for the prophylaxis of organ rejection in paediatric patients with a body surface area of greater than or equal to 1.25 square metres, receiving allogeneic renal transplants.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - mycophenolate mofetil, quantity: 250 mg - capsule - excipient ingredients: croscarmellose sodium; magnesium stearate; indigo carmine; purified water; titanium dioxide; gelatin; iron oxide red; sodium lauryl sulfate; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - mycophenolate mofetil is indicated for the prophylaxis of solid organ rejection in adults receiving allogeneic organ transplants.,mycophenolate mofetil is indicated for the prophylaxis of organ rejection in paediatric patients (2 to 18 years) receiving allogeneic renal transplants.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - mycophenolate mofetil, quantity: 250 mg - capsule - excipient ingredients: magnesium stearate; pregelatinised maize starch; titanium dioxide; povidone; croscarmellose sodium; gelatin; indigo carmine; iron oxide red; iron oxide yellow - mycophenolate sandoz is indicated for the prophylaxis of solid organ rejection in adults receiving allogeneic organ transplants. . mycophenolate sandoz is indicated for the prophylaxis of organ rejection in paediatric patients (6 to 18 years) receiving allogeneic renal transplants.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - mycophenolate mofetil, quantity: 500 mg - tablet, film coated - excipient ingredients: povidone; magnesium stearate; microcrystalline cellulose; croscarmellose sodium; hyprolose; purified talc; titanium dioxide; hypromellose; iron oxide red; iron oxide black; macrogol 400; indigo carmine aluminium lake - prophylaxis of solid organ rejection in adults receiving allogeneic organ transplants. prophylaxis of organ rejection in paediatric patients (with a body surface area > 1.5 m2) receiving allogeneic renal transplants.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - mycophenolate mofetil, quantity: 500 mg - tablet - excipient ingredients: microcrystalline cellulose; croscarmellose sodium; colloidal anhydrous silica; magnesium stearate; titanium dioxide; hypromellose; hyprolose; iron oxide red; iron oxide black; macrogol 400 - mycophenolate mofetil is indicated for the prophylaxis of solid organ rejection in adults receiving allogeneic organ transplants.,mycophenolate mofetil is indicated for the prophylaxis of organ rejection in paediatric patients (2 to 18 years) receiving allogeneic renal transplants.

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - mycophenolate mofetil, quantity: 500 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; microcrystalline cellulose; hyprolose; povidone; purified talc; magnesium stearate; titanium dioxide; hypromellose; iron oxide red; iron oxide black; macrogol 400; indigo carmine aluminium lake - prophylaxis of solid organ rejection in adults receiving allogeneic organ transplants. prophylaxis of organ rejection in paediatric patients (with a body surface area > 1.5 m2) receiving allogeneic renal transplants.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - mycophenolate mofetil, quantity: 250 mg - capsule, hard - excipient ingredients: pregelatinised maize starch; microcrystalline cellulose; croscarmellose sodium; sodium lauryl sulfate; silicon dioxide; magnesium stearate; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; iron oxide black; ethanol; shellac; sulfuric acid; titanium dioxide; indigo carmine; iron oxide yellow; sorbitan monolaurate; iron oxide red; potable water; gelatin - ceptolate (mycophenolate mofetil) is indicated for the prophylaxis of solid organ rejection in adults receiving allogeneic organ transplants. ceptolate (mycophenolate mofetil) is indicated for the prophylaxis of organ rejection in paediatric patients with a body surface area of greater than or equal to 1.25 square metres, receiving allogeneic renal transplants.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - mycophenolate mofetil, quantity: 500 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; microcrystalline cellulose; hyprolose; povidone; purified talc; magnesium stearate; titanium dioxide; hypromellose; iron oxide red; iron oxide black; macrogol 400; indigo carmine aluminium lake - prophylaxis of solid organ rejection in adults receiving allogeneic organ transplants. prophylaxis of organ rejection in paediatric patients (with a body surface area > 1.5 m2) receiving allogeneic renal transplants.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - mycophenolate mofetil, quantity: 500 mg - tablet, film coated - excipient ingredients: povidone; magnesium stearate; microcrystalline cellulose; croscarmellose sodium; hyprolose; purified talc; titanium dioxide; hypromellose; iron oxide red; iron oxide black; macrogol 400; indigo carmine aluminium lake - prophylaxis of solid organ rejection in adults receiving allogeneic organ transplants. prophylaxis of organ rejection in paediatric patients (with a body surface area > 1.5 m2) receiving allogeneic renal transplants.